Although the molecular detail about how chidamide decreases HMGB1 expression in AML cells remains to be elucidated, our results provide experimental clue for targeting HMGB1 expression using chidamide as a novel strategy in AML therapy. The gene discussed is HMGB1; the disease is acute myeloid leukemia.